Indrayani Biotech
- Market cap
- ₹ 65 Cr.
- P/E
- 31.4x
- P/B
- 0.55x
- 52-week range
- 6.69 – 18.05
- ROE
- 3%
- ROCE
- 4%
- Dividend yield
- 0%
- Debt / equity
- 1.76
- Sector
- Agricultural Food & other Products
- Industry
- Other Agricultural Products
- Listed on
- BSE
About
Indrayani Biotech Limited is engaged in the business operations of food and hospitality, dairy, healthcare and pharmaceutical, engineering, biotechnology, agriculture, and infrastructure. It provides a full range of food supply services on a contract basis to colleges and universities, hospitals and healthcare institutions, corporate offices, industries, among others. It markets and sells microorganism-based bio fertilizers, bio-pest controllers, bio-fortified vermi compost and bio-fortified coirpith to farmers. Its dairy unit offers skimmed milk powder, milk protein concentrates, milk whey powder, whey powder, whey protein concentrates, evaporated milk, whole milk powder, dairy whitener and casein. It operates hospitals, clinics, pharma companies, and pharma marketing companies. It is also engaged in corporate farming and trades agricultural commodities for the group's companies and external entities. It promotes commercial and residential infrastructure projects.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Other Agricultural Products: 90 companies →Indrayani Biotech against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)31.4 against a typical 14.5: pricier than most peers (1st = cheapest).63rd of 88
- Sales growth−25.3% against a typical +19.1% from a year earlier.55th of 68
- Share price, 3 months+11% against a typical −1.7%.18th of 81
- Size₹ 65.5 Cr. market value against a typical ₹ 63 Cr. (1st = largest).42nd of 85
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42 | 40 | 39 | 44 | 32 | 31 | 17 | 51 | 29 | 36 | 35 | 38 |
| Expenses | 40 | 33 | 36 | 34 | 26 | 26 | 14 | 56 | 27 | 34 | 32 | 36 |
| Operating Profit | 3 | 7 | 3 | 10 | 6 | 5 | 3 | −6 | 2 | 2 | 3 | 2 |
| OPM % | 6% | 18% | 8.8% | 22.9% | 19% | 16.6% | 16.9% | −11.4% | 7.5% | 6.8% | 8% | 5.9% |
| Other Income | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 1 | 2 | 1 | 1 |
| Interest | 2 | 1 | 1 | 6 | 1 | 1 | 1 | 7 | 2 | 2 | 2 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 4 | 3 | 1 | −2 | 1 | 1 | 1 | 1 |
| Profit before tax | −0 | 6 | 1 | 5 | 1 | 1 | 0 | −8 | 0 | 1 | 0 | −1 |
| Tax % | 15.8% | 0% | 0% | 0% | 9.6% | −1.7% | 18.6% | 2.5% | 23.8% | 14.2% | 21.4% | −187.4% |
| Net Profit | −0 | 6 | 1 | 5 | 1 | 1 | 0 | −9 | 0 | 1 | 0 | 1 |
| EPS in Rs | −0.08 | 0.94 | 0.13 | 0.5 | 0.11 | 0.16 | 0.03 | −1.09 | 0.02 | 0.05 | 0.02 | 0.13 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 46%
- 3 Years
- −5%
- TTM
- 6%
- 10 Years
- —
- 5 Years
- 18%
- 3 Years
- −38%
- TTM
- 135%
- 10 Years
- 4%
- 5 Years
- −19%
- 3 Years
- −44%
- TTM
- —
- 10 Years
- —
- 5 Years
- 6%
- 3 Years
- 1%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Indrayani Biotech | ₹ 8.25 | ₹ 65 Cr. | 31.4x | 0.6x | 3% | — |
| ITC Hotels | ₹ 156.05 | ₹ 32,505 Cr. | 40.7x | 3.1x | — | 20.4% |
| EIH | ₹ 290.25 | ₹ 18,151 Cr. | 33.6x | 4x | 12.7% | 22.4% |
| Chalet Hotels | ₹ 790.00 | ₹ 17,306 Cr. | 29.2x | 5.1x | 19.1% | 23.3% |
| Leela Palaces Hotels & Resorts | ₹ 575.10 | ₹ 19,317 Cr. | 38.6x | 2.5x | — | 26.4% |
| Ventive Hospitality | ₹ 558.20 | ₹ 13,049 Cr. | 33.7x | 2.6x | 8.3% | 20.4% |
Management
- Kunisetty Rao
- Chief Financial Officer
- Kasiraman Sayee Sundar
- Managing Director, Executive Director
- Swaminathan Govindarajan
- Whole-time Director
- Muthukrishnan Ramesh
- Whole-time Director
Prices are delayed and for information only. Nothing on this page is investment advice.